RIG-I mimetics are thus being explored as attractive agents for clinical translation to stimulate de novo inflammation, DCs activation and T-cell priming, particularly in poorly immunogenic, non-T-cell inflamed tumours. This evidence concerns the gene RIGI and neoplasm.